Filter Results:
(56)
Show Results For
- All HBS Web
(142)
- People (1)
- News (57)
- Research (56)
- Events (1)
- Multimedia (5)
- Faculty Publications (28)
Show Results For
- All HBS Web
(142)
- People (1)
- News (57)
- Research (56)
- Events (1)
- Multimedia (5)
- Faculty Publications (28)
Sort by
- October 2023 (Revised May 2024)
- Case
Thermo Fisher Scientific: Foray into Contract Research
By: Satish Tadikonda, William Marks and Kevin Emancipator
After publicly declaring that they would not enter the contract research organization (CRO) business in 2017, Thermo Fisher purchased Pharmaceutical Product Development (PPD), one of the biggest players in the CRO space, in 2021. Much had changed in the intervening... View Details
Keywords: Mergers and Acquisitions; Customer Focus and Relationships; Corporate Strategy; Organizational Change and Adaptation; Biotechnology Industry
Tadikonda, Satish, William Marks, and Kevin Emancipator. "Thermo Fisher Scientific: Foray into Contract Research." Harvard Business School Case 824-073, October 2023. (Revised May 2024.)
- Article
Drive Innovation with Better Decision-Making
By: Linda A. Hill, Emily Tedards and Taran Swan
Despite their embrace of agile methods, many firms striving to innovate are struggling to produce breakthrough ideas. A key culprit, according to the authors, is an outdated, inefficient approach to decision-making. Today’s discovery-driven innovation processes involve... View Details
Keywords: Innovation and Invention; Decision Making; Decision Choices and Conditions; Organizational Change and Adaptation
Hill, Linda A., Emily Tedards, and Taran Swan. "Drive Innovation with Better Decision-Making." Harvard Business Review 99, no. 6 (November–December 2021): 70–79.
- March 2023
- Teaching Note
Hikma Pharmaceuticals Governance Journey
By: Suraj Srinivasan and Jonah Goldberg
Teaching Note for HBS Case No. 318108. The case opens with Said Darwazah, chairman and CEO of Hikma Pharmaceuticals, the multinational generics company, anticipating the company’s 2017 AGM and reflecting on changes made over the previous year to address concerns... View Details
Keywords: Jordan; Emerging Market; Private Sector; For-profit Firms; Boards Of Directors; Pharmaceuticals; Remuneration; Shareholder Engagement; Corporate Governance; Governing and Advisory Boards; Business and Shareholder Relations; Executive Compensation; Business Growth and Maturation; Pharmaceutical Industry; Jordan
- March 2011 (Revised June 2012)
- Case
Office of Technology Transfer - Shanghai Institutes for Biological Sciences
By: Willy Shih, Sen Chai, Kamen Bliznashki and Courtney Hyland
Gordon Zong is trying to teach Chinese universities and research institutes how to do effective technology transfer and IP licensing, but he is trying to do it in an environment with weak property rights and an underdeveloped support infrastructure. As the managing... View Details
Keywords: Multinational Firms and Management; Patents; Knowledge Management; Law Enforcement; Business and Government Relations; Research and Development; Biotechnology Industry; Pharmaceutical Industry; China
Shih, Willy, Sen Chai, Kamen Bliznashki, and Courtney Hyland. "Office of Technology Transfer - Shanghai Institutes for Biological Sciences." Harvard Business School Case 611-057, March 2011. (Revised June 2012.)
- August 2023
- Case
Constellation Pharmaceuticals: Corporate Development at a Novel Therapeutic Company
By: Satish Tadikonda and Brad Prosek
Constellation Pharmaceuticals was a company focused on epigenetic therapies for cancer patients. Despite a promising start and an early deal with a leading biopharma company, the company weathered twin setbacks in the end of a major research collaboration and the... View Details
Keywords: Mergers and Acquisitions; Health Care and Treatment; Organizational Change and Adaptation; Research and Development; Business Strategy; Partners and Partnerships; Goals and Objectives; Pharmaceutical Industry; United States
Tadikonda, Satish, and Brad Prosek. "Constellation Pharmaceuticals: Corporate Development at a Novel Therapeutic Company." Harvard Business School Case 824-032, August 2023.
- November 2022
- Case
The Battle Among Channels for Marketing Pharmaceuticals: UpScript, Pharmacy Benefit Managers, and Direct-to-Consumer Sales
By: Regina E. Herzlinger and Tiffany Farrell
Can an online, direct-to-consumer pharmacy both improve the quality and speed of care for patients who need branded drugs and stabilize profits for pharmaceutical manufacturers? UpScript, after years spent achieving legal and regulatory compliance and simultaneous... View Details
Keywords: DTC; Internet and the Web; Marketing Channels; Customer Value and Value Chain; Governing Rules, Regulations, and Reforms; Competitive Strategy; Service Delivery; Growth and Development Strategy; Pharmaceutical Industry; Health Industry; Retail Industry
Herzlinger, Regina E., and Tiffany Farrell. "The Battle Among Channels for Marketing Pharmaceuticals: UpScript, Pharmacy Benefit Managers, and Direct-to-Consumer Sales." Harvard Business School Case 323-031, November 2022.
- February 2018 (Revised October 2024)
- Case
Hikma Pharmaceuticals Governance Journey
By: Lynn Paine, Suraj Srinivasan and Gamze Yucaoglu
The case opens with Said Darwazah, chairman and CEO of Hikma Pharmaceuticals, the multinational generics company, anticipating the company’s 2017 AGM and reflecting on changes made over the previous year to address concerns expressed by proxy advisors and some... View Details
Keywords: Boards Of Directors; Pharmaceuticals; Remuneration; Shareholder Engagement; Corporate Governance; Governing and Advisory Boards; Business and Shareholder Relations; Executive Compensation; Business Growth and Maturation; Emerging Markets; Private Sector; For-Profit Firms; Pharmaceutical Industry; Jordan
Paine, Lynn, Suraj Srinivasan, and Gamze Yucaoglu. "Hikma Pharmaceuticals Governance Journey." Harvard Business School Case 318-108, February 2018. (Revised October 2024.)
- January 2017 (Revised October 2018)
- Case
Novartis: A Transformative Deal
By: David Collis and Ashley Hartman
When Joe Jimenez became CEO of Swiss-based Novartis in 2010, replacing longtime CEO Dan Vasella, he assumed control of one of the top pharmaceutical companies in the world. Vasella, an avowed advocate of diversification, had expanded the scope of the company and... View Details
Keywords: Novartis; GlaxoSmithKline; Asset Swap; Acquisitions; Divestiture; Strategy Alignment; Pharmaceuticals; Strategy; Business Strategy; Corporate Strategy; Diversification; Consolidation; Mergers and Acquisitions; Pharmaceutical Industry
Collis, David, and Ashley Hartman. "Novartis: A Transformative Deal." Harvard Business School Case 717-453, January 2017. (Revised October 2018.)
- January 2018 (Revised January 2019)
- Case
ZappRx
By: Jeffrey J. Bussgang and Olivia Hull
In October 2015, ZappRx founder Zoe Barry is deciding between two business models for her health technology start-up. Her product, a software application that aims to expedite the prescription fulfillment process for patients with rare diseases, has attracted interest... View Details
- September 2020
- Case
Minerva 2020: Clinical Trials
By: John R. Wells and Benjamin Weinstock
In March 2020, Dr. Cynthia Bamdad, founder and CEO of Minerva Biotechnologies Inc. (Minerva), was reviewing the first results of human clinical trials for the company’s novel CAR-T drug therapeutic, one of the first ever to target solid cancer tumors. The results... View Details
Keywords: Biotechnology; Strategic Decision Making; Entrepreneurship; Health Testing and Trials; Decision Choices and Conditions; Strategy
Wells, John R., and Benjamin Weinstock. "Minerva 2020: Clinical Trials." Harvard Business School Case 721-391, September 2020.
- 13 Jun 2017
- First Look
First Look at New Research and Ideas, June 13
May 2017 American Economic Review: Papers and Proceedings Immigration and the Rise of American Ingenuity By: Akcigit, Ufuk, John Grigsby, and Tom Nicholas Abstract—We build on the analysis in Akcigit, Grigsby, and Nicholas (2017) by using U.S. patent and census data to... View Details
Keywords: Sean Silverthorne
- 17 Oct 2023
- HBS Case
With Subscription Fatigue Setting In, Companies Need to Think Hard About Fees
about the benefits of switching to a subscription model. “There can be this hesitancy to move all out,” says Ofek. “But as the benefits of the subscription model become evident, [more] firms find it worthwhile to do it.” You Might Also Like: Could a Business Model Help... View Details
- 31 Mar 2023
- Research & Ideas
Can a ‘Basic Bundle’ of Health Insurance Cure Coverage Gaps and Spur Innovation?
continuing to address health insurance problems piecemeal will only create further fractures. The US needs to work on fostering “universal access to innovative care in an affordable system,” they say. You Might Also Like: The FDA’s Speedy Drug Approvals Are Safe: A... View Details
- 19 Sep 2023
- Research & Ideas
What Chandrayaan-3 Says About India's Entrepreneurial Approach to Space
appeared in the Harvard Gazette. Interview has been edited for clarity and length. You Might Also Like: 5 Qualities That Help Companies Thrive for Decades—Even Centuries When Experts Play It Too Safe: Innovation Lessons from a NASA Experiment Could a Business Model... View Details
- 30 May 2024
- Research & Ideas
Racial Bias Might Be Infecting Patient Portals. Can AI Help?
differences in response to different types of customers,” Stern says. “To the extent those exist, that means you’re not serving a certain group of customers, and you’re potentially leaving money on the table.” You Might Also Like: The FDA’s Speedy Drug Approvals Are... View Details
- 12 Jun 2018
- Research & Ideas
In a Landscape of 'Me Too' Drug Development, What Spurs Radical Innovation?
not difficult for pharma firms. Companies tended to “either have projects on the shelf or projects that they are excited to go do when they get a little more buffer or get a little more cash,” Krieger says. Ask yourself a question What’s... View Details
- 15 Nov 2022
- Book
Stop Ignoring Bad Behavior: 6 Tips for Better Ethics at Work
In 1995, Purdue Pharma began selling a powerful and addictive opioid drug called OxyContin. The company was aware that the drug, which was marketed to doctors as a safe way to manage chronic pain, was a potent narcotic that could quickly... View Details
Keywords: by Pamela Reynolds
- Research Summary
Career Histories and the Biotechnology Industry
Professor Higgins' other major project focuses on the consequences of individuals' career experiences for firms and industries. This second research stream centers on the careers of executives in the biotechnology industry.
Professor Higgins has written... View Details
- 22 Nov 2004
- Research & Ideas
Side Effects: The Case of Propecia
wives, believing such campaigns would not be cost effective. As Wosinska put the problem: "How does a pharma talk to barbers?" In the end, first-year sales beat internal estimates, thanks to pent-up demand. Propecia is now a... View Details
- 18 Jul 2018
- Research & Ideas
No More General Tso's? A Threat to 'Knowledge Recombination'
pharmaceutical companies, which had been flying in scientists from China and India who, like Cohly, brought knowledge of native herbs. Some pharma companies were able to earn exemptions from the H1-B limits. Choudhury and Kim used this... View Details